Literature DB >> 28083286

Hepatitis C: A Projection of the Healthcare and Economic Burden in the UK.

Bhanu Patruni, Ellen Nolte.   

Abstract

Work presented in this article sought to assess the healthcare and economic burden of the hepatitis C virus (HCV) infection in the United Kingdom. It used a cohort simulation model to estimate the prevalence of HCV infection in the UK, including the number of persons who live with HCV infection at different disease stages, and the number of deaths that can be attributed to HCV infection through to 2035. It further assessed the healthcare and societal costs that are associated with HCV infection under different scenarios of diagnosis and treatment rates.

Entities:  

Year:  2013        PMID: 28083286      PMCID: PMC4945231     

Source DB:  PubMed          Journal:  Rand Health Q        ISSN: 2162-8254


  4 in total

1.  Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.

Authors:  Necati Örmeci; Simten Malhan; İsmail Balık; Gül Ergör; Homie Razavi; Sarah Robbins
Journal:  Hepatol Int       Date:  2017-10-12       Impact factor: 6.047

2.  Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

Authors:  Mirjana R Jovanovic; Aleksandar Miljatovic; Laslo Puskas; Slobodan Kapor; Dijana L Puskas
Journal:  Front Pharmacol       Date:  2017-06-30       Impact factor: 5.810

3.  Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study.

Authors:  Katharina Büsch; Fredrik Hansson; Michelle Holton; Martin Lagging; Johan Westin; Jan Kövamees; Matti Sällberg; Jonas Söderholm
Journal:  BMJ Open       Date:  2020-09-02       Impact factor: 2.692

4.  Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.

Authors:  Katherine Heath
Journal:  Clinicoecon Outcomes Res       Date:  2018-09-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.